A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year

• Willingness to maintain same hair style, length and hair color during study

• Willingness to have micro-dot-tattoo applied to scalp (Stage 2 only)

Exclusion Criteria:

• Drug or alcohol abuse within 12 months

• HIV positive

• Received hair transplants or had scalp reductions

• Use of hair weaves, hair extensions or wigs within 3 months

• Use of minoxidil (oral or topical) and/or low level light treatment "combs" for hair growth within the last 6 months, or expected use during the study

• Application of topical steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) to scalp within 4 weeks